Gray matter abnormalities in Major Depressive Disorder: a meta-analysis of voxel based morphometry studies.

Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Victoria, Australia.
Journal of affective disorders (Impact Factor: 3.76). 04/2011; 138(1-2):9-18. DOI: 10.1016/j.jad.2011.03.049
Source: PubMed

ABSTRACT Voxel-based morphometry (VBM) has been widely used to quantify structural brain changes associated with Major Depressive Disorder (MDD). While some consistent findings have been reported, individual studies have also varied with respect to the key brain regions affected by the illness, and how these abnormalities are related to patients' clinical characteristics. Here, we aimed to identify those brain regions that most consistently showed gray matter anomalies in MDD, and their clinical correlates, using meta-analytic techniques.
A systematic search of VBM studies was applied in MDD. Signed differential mapping, a new coordinate based neuroimaging meta-analysis technique, was applied to data collated from a total of 23 studies comparing regional gray matter volumes of 986 MDD patients and 937 healthy controls.
Gray matter was significantly reduced in a confined cluster located in the rostral anterior cingulate cortex (ACC). There were also gray matter reductions in dorsolateral and dorsomedial prefrontal cortex and decrease in the latter region was evident in patients with multiple-episodes. Amygdala and parahippocampal gray matter volumes were significantly reduced in studies including patients with comorbid anxiety disorders, as well as in first-episode/drug free samples.
Gray matter reduction in rostral ACC was the most consistent finding in VBM studies of MDD. The evidence for reductions in other regions within fronto-subcortical and limbic regions was less consistent. The associations between these gray matter anomalies and clinical characteristics, particularly measures relating to illness duration, suggest that chronic MDD has a robust and deleterious, albeit spatially focal, effect on brain structure.

  • Source
    Psychopharmacology 10/2014; · 4.06 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: -This chart review examined clinical, treatment parameter, and outcome data from 185 outpatients with medication-resistant major depression who received either 10 Hz (30 min) or intermittent theta burst (6 min) rTMS of the bilateral dorsomedial prefrontal cortex, under MRI guidance, at 120% resting motor threshold, in a single Canadian clinic (the Toronto Western Hospital) from April, 2011 to February, 2014.-There were no seizures or other serious adverse events over 7912 total runs of stimulation in 185 unique patients (10 Hz: 4274 runs, 2137 sessions, 98 patients; iTBS: 3638 runs, 1819 sessions, 87 patients). There were no significant differences between 10 Hz and iTBS patients in the rates of discontinuation for lack of response, adverse symptoms, or unspecified reasons.-Dichotomous outcomes did not differ significantly between groups (Response/remission rates: BDI-II: 10 Hz, 40.6%/29.2%; iTBS, 43.0%/31.0%. HamD17: 10 Hz, 50.6%/38.5%; iTBS, 48.5%/27.9%). On continuous outcomes, there was no significant difference between groups in pre-treatment or post-treatment scores, or percent improvement on either BDI-II of HamD17. Mixed-effects modelling revealed no significant group-by-time interaction on either measure.-Outcomes were non-normally distributed in both groups, with a trimodal distribution into non-responders, partial responders, and strong responders apparent on kernel density estimates of the distribution of outcomes in both groups on BDI-II and HamD17 measures.-Non-parametric comparisons of the cumulative distribution functions for the 10 Hz and iTBS groups also revealed no significant differences in outcomes on either BDI-II or HamD17 measures.-In terms of pace of improvement, mixed-effects models found no significant group by time interaction over the course of treatment, on either the BDI-II or HamD17 measures.-The results suggest that iTBS may be as safe and well-tolerated as 10 Hz stimulations requiring 5 times as many pulses and 5 times as much time to administer, while achieving equivalent outcomes. The implications of this finding for rTMS treatment costs and clinic capacities could be substantial. A randomized controlled trial comparing conventional 10 Hz stimulation to briefer iTBS protocols, at the conventional target in the left DLPFC, may be warranted.
    Brain Stimulation 11/2014; · 4.54 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Major depressive disorder (MDD) is associated with cognitive dysfunction encompassing several domains, including memory, executive function, processing speed and attention. Cognitive deficits persist in a significant proportion of patients even in remission, compromising psychosocial functioning and workforce performance. While monoaminergic antidepressants may improve cognitive performance in MDD, most antidepressants have limited clinical efficacy. The overarching aims of this review were: (1) to synthesize extant literature on putative biological pathways related to cognitive dysfunction in MDD and (2) to review novel neurotherapeutic targets for cognitive enhancement in MDD. We found that reciprocal and overlapping biological pathways may contribute to cognitive dysfunction in MDD, including an hyperactive hypothalamic-pituitary-adrenal axis, an increase in oxidative and nitrosative stress, inflammation (eg, enhanced production of pro-inflammatory cytokines), mitochondrial dysfunction, increased apoptosis as well as a diminished neurotrophic support. Several promising neurotherapeutic targets were identified such as minocycline, statins, anti-inflammatory compounds, N-acetylcysteine, omega-3 poliunsaturated fatty acids, erythropoietin, thiazolidinediones, glucagon-like peptide-1 analogues, S-adenosyl-l-methionine (SAMe), cocoa flavonols, creatine monohydrate and lithium. Erythropoietin and SAMe had pro-cognitive effects in randomized controlled trials (RCT) involving MDD patients. Despite having preclinical and/or preliminary evidences from trials suggesting possible efficacy as novel cognitive enhancing agents for MDD, no RCT to date was performed for most of the other therapeutic targets reviewed herein. In conclusion, multiple biological pathways are involved in cognitive dysfunction in MDD. RCTs testing genuinely novel pro-cognitive compounds for MDD are warranted.
    CNS & neurological disorders drug targets. 11/2014;


Available from
Jun 2, 2014